 |
인쇄하기
취소
|
LG, Mochida announce development and licensing agreement for biosimilar
LG Life Sciences (LGLS) announced Wednesday that it has granted Japan based Mochida Pharmaceutical Co. an exclusive license to develop, register and market a biosimilar drug developed by LGLS in Korea and Japan.
The terms of the agreement include an upfront payment and and additional milestone payments by Mochida to LGLS, and LGLS will supply the drug to Mochida after commercialization.
“...
The terms of the agreement include an upfront payment and and additional milestone payments by Mochida to LGLS, and LGLS will supply the drug to Mochida after commercialization.
“...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.